{"id":51076,"date":"2022-11-21T14:02:20","date_gmt":"2022-11-21T13:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/"},"modified":"2022-11-21T14:02:20","modified_gmt":"2022-11-21T13:02:20","slug":"graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/","title":{"rendered":"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th<\/sup> Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nThe fireside chat will be webcast live from Graphite Bio\u2019s website at www.graphitebio.com<\/a> in the Investors section. A replay of the webcast will be archived and available following the event.\n<\/p>\n

\nAbout Graphite Bio<\/b>\n<\/p>\n

\nGraphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine\u2019s most elusive goals: to precisely \u201cfind & replace\u201d any gene in the genome. Graphite Bio\u2019s UltraHDR\u2122 gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.\n<\/p>\n

\nLearn more about Graphite Bio by visiting www.graphitebio.com<\/a> and following the company on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Stephanie Yao
\n
Graphite Bio
\n
ir@graphitebio.com<\/a>\n<\/p>\n

\nMedia:<\/b>
Sheryl Seapy
\n
Real Chemistry
\n
media@graphitebio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51076","6":"format-standard","7":"category-industry"},"yoast_head":"\nGraphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T13:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221116005881\/en\/1622747\/21\/Graphite_Bio_Primary_Logo_RGB_M01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference\",\"datePublished\":\"2022-11-21T13:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/\"},\"wordCount\":285,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005881\\\/en\\\/1622747\\\/21\\\/Graphite_Bio_Primary_Logo_RGB_M01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/\",\"name\":\"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005881\\\/en\\\/1622747\\\/21\\\/Graphite_Bio_Primary_Logo_RGB_M01.jpg\",\"datePublished\":\"2022-11-21T13:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005881\\\/en\\\/1622747\\\/21\\\/Graphite_Bio_Primary_Logo_RGB_M01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005881\\\/en\\\/1622747\\\/21\\\/Graphite_Bio_Primary_Logo_RGB_M01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T13:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221116005881\/en\/1622747\/21\/Graphite_Bio_Primary_Logo_RGB_M01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference","datePublished":"2022-11-21T13:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/"},"wordCount":285,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005881\/en\/1622747\/21\/Graphite_Bio_Primary_Logo_RGB_M01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/","url":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/","name":"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005881\/en\/1622747\/21\/Graphite_Bio_Primary_Logo_RGB_M01.jpg","datePublished":"2022-11-21T13:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221116005881\/en\/1622747\/21\/Graphite_Bio_Primary_Logo_RGB_M01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221116005881\/en\/1622747\/21\/Graphite_Bio_Primary_Logo_RGB_M01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/graphite-bio-announces-participation-in-evercore-isi-5th-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51076"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51076\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}